| Abstrakt: |
Alchemab Therapeutics, a pharmaceutical company focused on identifying and developing therapeutic antibodies, has announced that Jane Osbourn, the company's Chief Scientific Officer, will take over as Chief Executive Officer. Osbourn has over 30 years of experience in the biopharmaceutical industry and has played a key role in the development of antibody therapies. She has received several awards for her contributions to drug discovery and biotechnology. Alchemab's Chair and Managing Partner expressed support for Osbourn's leadership and expertise, while the outgoing CEO praised her scientific and organizational skills. The company aims to continue its growth and develop groundbreaking treatments for patients. [Extracted from the article] |
